News Sentiment

BNGO sentiment intelligence

Bionano Genomics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 1.20 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+4.3% over one week, +3.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Precision Trading with Bionano Genomics Inc. (BNGO) Risk Zones

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction 4.3% Price confirming higher
Trend fit Trend inactive 3.4% over four weeks
Fair value -97.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
TradingKey 7
TradingView 5
GlobeNewswire 4
Market source 4
The Globe and Mail 3
Investing.com 3
The Manila Times 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 10
Analyst action 4
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Providence Business News Direct company coverage

Nabsys selects first-ever chief medical officer

Nabsys 2.0 LLC, an electronic genome-mapping company, has appointed Alka Chaubey as its first chief medical and genomics officer. Chaubey, formerly CMO of Bionano Genomics Inc., will lead Nabsys' medical and scientific affairs, industry collaborations, and expand electronic genom

Tone
Positive 66/100
Event
Market update
Published
13 Jul 2026 02:11
Source
Providence Business News
TradingView Direct company coverage

Price to sales forward of Bionano Genomics, Inc. – NASDAQ:BNGO

This article provides financial information for Bionano Genomics, Inc. (NASDAQ: BNGO), specifically focusing on its price-to-sales forward metric. The content, sourced from TradingView, indicates "No trades" and "Market closed," suggesting a financial snapshot rather than live ma

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 11:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Bionano Genomics, Inc. – NASDAQ:BNGO

This page provides financial information for Bionano Genomics, Inc. (NASDAQ: BNGO), specifically focusing on its forward price-to-book ratio. The content is primarily a data placeholder from TradingView, indicating that the value and changes for this metric are available for spec

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:40
Source
TradingView
MSN Direct company coverage

Bionano Genomics, Inc. (BNGO) reports Q1 loss, tops revenue estimates

Bionano Genomics, Inc. (BNGO) announced a narrower-than-expected loss for the first quarter, reporting a loss of 6 cents per share, which is 2 cents better than the Zacks Consensus Estimate. The company also surpassed revenue expectations, bringing in $8.95 million against an est

Tone
Positive 61/100
Event
Earnings
Published
25 Jun 2026 17:11
Source
MSN
TradingView Direct company coverage

Bionano Genomics, Inc. Actuals & Estimates (NASDAQ:BNGO)

This article provides an overview of Bionano Genomics, Inc. (NASDAQ: BNGO) stock, including its current price, market capitalization, and analyst forecasts. It details financial metrics such as earnings per share and revenue, notes the company does not pay dividends, and offers i

Tone
Negative 38/100
Event
Earnings
Published
25 Jun 2026 15:11
Source
TradingView
TradingView Direct company coverage

BNGO Forecast — Price Target — Prediction for 2027

This article provides a forecast for Bionano Genomics, Inc. (BNGO) stock, including analyst price targets, historical performance data, and financial metrics. Analysts project a maximum price of $6.00 and a minimum of $4.00 for BNGO. The company's stock has seen significant decli

Tone
Negative 36/100
Event
Analyst action
Published
25 Jun 2026 14:11
Source
TradingView
Simply Wall Street Direct company coverage

BNGO: Reproductive And Prenatal Genomic Advances Will Drive Future Upside

Bionano Genomics (BNGO) is seeing its fair value trimmed to $5.00 from $5.50 by analysts, despite advancements in reproductive and prenatal genetics using optical genome mapping (OGM). Recent studies highlight OGM's effectiveness in identifying genetic causes of infertility and i

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:10
Source
Simply Wall Street
Investing.com South Africa Direct company coverage

Bionano Genomics appoints Alex Hastie as chief scientific officer By Investing.com

Bionano Genomics has appointed Alex Hastie, Ph.D., as its new Chief Scientific Officer, effective July 20. Dr. Hastie, who previously spent 14 years at Bionano contributing to its optical genome mapping technology, will now lead the company's scientific strategy, innovation, and

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 19:09
Source
Investing.com South Africa
Stock Titan Direct company coverage

Bionano brings back OGM pioneer to lead science strategy July 20

Bionano (NASDAQ: BNGO) has appointed Alex Hastie, Ph.D., as its Chief Scientific Officer, effective July 20, 2026. Dr. Hastie, a pivotal figure in Bionano's optical genome mapping (OGM) technology for 14 years, will now lead the company's global scientific strategy, innovation, a

Tone
Positive 74/100
Event
Market update
Published
24 Jun 2026 12:40
Source
Stock Titan
TradingView Direct company coverage

Bionano appoints Alex Hastie as Chief Scientific Officer to lead global science strategy

Bionano has appointed Alex Hastie, Ph.D. as Chief Scientific Officer, effective July 20, 2026. Hastie, who previously helped develop Bionano's optical genome mapping technology, will now lead the company's global scientific strategy, focusing on expanding clinical research applic

Tone
Positive 72/100
Event
Market update
Published
24 Jun 2026 12:40
Source
TradingView
Stock Titan Direct company coverage

Alex Hastie returns as Chief Scientific Officer at Bionano Genomics (NASDAQ: BNGO)

Bionano Genomics, Inc. (NASDAQ: BNGO) announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer, effective July 20, 2026. Hastie, who previously spent 14 years at Bionano and was instrumental in developing its optical genome mapping (OGM) technologies, will

Tone
Positive 71/100
Event
Market update
Published
24 Jun 2026 12:40
Source
Stock Titan
The Manila Times Direct company coverage

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

Bionano Genomics reported a 67% year-over-year increase in studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference, indicating growing global adoption. The 35 studies, up from 21 in 2025, originated from 17 countries across

Tone
Positive 93/100
Event
Market update
Published
18 Jun 2026 20:16
Source
The Manila Times
Stock Titan Direct company coverage

Bionano’s genome-mapping studies jump to 35 at ESHG 2026

Bionano (Nasdaq: BNGO) announced a 67% year-over-year increase in studies featuring its optical genome mapping (OGM) technology at ESHG 2026, reaching 35 studies from 17 countries. This growth highlights expanding global adoption across various research areas like rare genetic di

Tone
Positive 75/100
Event
Market update
Published
18 Jun 2026 12:11
Source
Stock Titan
TradingKey Direct company coverage

Bionano Genomics Inc (BNGO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history of Bionano Genomics Inc (BNGO). It notes that the company has not distributed any dividends in the past five years. However, it lists several stock merger events, including a 60-to-1 merger scheduled for Januar

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 00:40
Source
TradingKey
TradingKey Direct company coverage

Bionano Genomics Inc (BNGO) Shareholder Structure: Major Shareholders & Institutional Holdings

The article details the shareholder structure of Bionano Genomics Inc (BNGO), listing its major shareholders and institutional holdings. Key shareholders include Lincoln Alternative Strategies LLC and GSA Capital Partners LLP, with breakdowns by shareholder type such as hedge fun

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

Bionano Genomics Inc (BNGO) Institutional Confidence

Bionano Genomics Inc (BNGO) has an institutional shareholding score of 3.00, placing it 132nd out of 204 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion has increased by 354.71% quarter-over-quarter, reaching 10.52%. James Simons is the

Tone
Positive 66/100
Event
Market update
Published
17 Jun 2026 22:11
Source
TradingKey
TradingKey Direct company coverage

Bionano Genomics Inc (BNGO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bionano Genomics Inc (BNGO) has an earnings forecast score of 8.00 and an average price target of $7.50, with a high of $8.00 and a low of $7.00. Based on two analysts, the stock has a "Buy" rating with a target price upside of +334.78%. The company's expected revenue for the nex

Tone
Positive 66/100
Event
Earnings
Published
17 Jun 2026 18:40
Source
TradingKey
The Manila Times Direct company coverage

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

Bionano Genomics announced 13 studies published in 2026, analyzing 730 samples, demonstrate the utility of optical genome mapping (OGM) for detecting structural variants in reproductive health and prenatal genetic disorders. These studies, conducted by independent research groups

Tone
Positive 95/100
Event
Market update
Published
11 Jun 2026 12:10
Source
The Manila Times
Stock Titan Direct company coverage

Infertility gene clues: 13 studies find hidden variants with Bionano mapping

Bionano announced that 13 independent studies published in 2026 utilized optical genome mapping (OGM) to analyze 730 samples in reproductive health and prenatal genetics. These studies demonstrated OGM's effectiveness in identifying structural variants often missed by standard me

Tone
Positive 72/100
Event
Market update
Published
11 Jun 2026 12:10
Source
Stock Titan